📗 Cite This Artifact
ID: hypothesis-h-fdb07848
Hypothesis
Sphingomyelin Synthase Activators for Raft Remodeling
Sphingomyelin Synthase Activators for Raft Remodeling starts from the claim that modulating SGMS1/SGMS2 within the disease context of neurodegeneration can redirect a disease-relevant process.
EvidencePending (0%)📖 23 cit🗣 1 debates✓ 13 support✗ 5 oppose
✓ All Quality Gates Passed
🧪 Overview
Mechanistic Overview
Sphingomyelin Synthase Activators for Raft Remodeling starts from the claim that modulating SGMS1/SGMS2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Sphingomyelin synthase (SMS) activation for membrane raft remodeling targets the pathological lipid imbalance at synaptic membranes — specifically the shift from sphingomyelin to ceramide — that disrupts synaptic signaling, promotes amyloidogenic processing, and drives neuronal apoptosis in neurodegenerative diseases. Sphingomyelin-Ceramide Balance at Synapses Synaptic membranes are organized into specialized lipid raft microdomains enriched in sphingomyelin, cholesterol, and specific gangliosides....
Mechanistic Overview
Sphingomyelin Synthase Activators for Raft Remodeling starts from the claim that modulating SGMS1/SGMS2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Sphingomyelin synthase (SMS) activation for membrane raft remodeling targets the pathological lipid imbalance at synaptic membranes — specifically the shift from sphingomyelin to ceramide — that disrupts synaptic signaling, promotes amyloidogenic processing, and drives neuronal apoptosis in neurodegenerative diseases. Sphingomyelin-Ceramide Balance at Synapses Synaptic membranes are organized into specialized lipid raft microdomains enriched in sphingomyelin, cholesterol, and specific gangliosides. These rafts serve as signaling platforms for: - Neurotransmitter receptors (NMDA-R, AMPA-R, mGluR5) that require raft localization for proper function - Neurotrophin receptors (TrkB, p75NTR) that signal survival versus death depending on raft partitioning - Synaptic vesicle fusion machinery that depends on raft composition for efficient neurotransmission The ratio of sphingomyelin to ceramide critically determines raft integrity and fluidity. Sphingomyelin provides structural rigidity and creates ordered domains that cluster signaling proteins. Ceramide, produced by sphingomyelin hydrolysis (via sphingomyelinases, SMases) or de novo synthesis, disrupts raft organization by creating highly ordered, rigid patches that exclude signaling proteins. Ceramide Accumulation in Neurodegeneration In Alzheimer's, Parkinson's, and ALS, the sphingomyelin-ceramide balance shifts dramatically toward ceramide: 1. Acid sphingomyelinase (ASM) upregulation: Inflammatory cytokines (TNF-α, IL-1β) and oxidative stress activate ASM, which hydrolyzes sphingomyelin to ceramide. In AD hippocampus, ASM activity is elevated 2-3 fold, and ceramide levels are 50-60% higher than age-matched controls. 2. Neutral sphingomyelinase 2 (nSMase2) activation: Amyloid-β oligomers directly activate nSMase2 at synaptic membranes, generating ceramide in situ. This local ceramide production disrupts the synaptic rafts where Aβ oligomers exert their toxicity, creating a feed-forward loop. 3. De novo ceramide synthesis: The serine palmitoyltransferase (SPT) pathway, rate-limited by SPTLC1/2 subunits, is upregulated in aging neurons. Increased de novo ceramide synthesis depletes the shared sphingolipid precursor pool, reducing sphingomyelin availability. 4. SMS downregulation: SGMS1 (Golgi-localized SMS1) and SGMS2 (plasma membrane-localized SMS2) convert ceramide back to sphingomyelin. Both enzymes are downregulated 30-40% in aging and neurodegeneration, removing the primary pathway for ceramide-to-sphingomyelin reconversion. The consequences of ceramide accumulation include: - BACE1 raft enrichment: Ceramide promotes BACE1 localization within lipid raft domains, increasing its access to APP and accelerating amyloid-β production - Apoptotic signaling: Ceramide activates PP2A (protein phosphatase 2A), which dephosphorylates Akt, suppressing survival signaling. Ceramide also activates the JNK pathway and promotes mitochondrial outer membrane permeabilization via BAX/BAK - Synaptic dysfunction: Ceramide-enriched patches exclude AMPA and NMDA receptors from postsynaptic densities, reducing synaptic strength - Exosome release: Ceramide drives inward budding of multivesicular body membranes, increasing exosome release. These exosomes carry and spread pathological protein seeds (tau, α-synuclein) between cells Therapeutic Strategy: SMS Activation Activating sphingomyelin synthases to convert excess ceramide back to sphingomyelin simultaneously addresses two problems: reducing toxic ceramide levels and restoring sphingomyelin needed for raft integrity. 1. SGMS1 transcriptional upregulation: SGMS1 is regulated by SREBP (sterol regulatory element-binding protein) and SP1 transcription factors. Oxysterols and certain LXR agonists increase SGMS1 expression. The challenge is achieving CNS-specific activation. 2. SGMS2 allosteric activators: SGMS2 at the plasma membrane directly converts ceramide to sphingomyelin where it's most needed — at synaptic membranes. Screening for SGMS2 allosteric activators is feasible given the enzyme's solved cryo-EM structure. 3. Sphingomyelinase inhibitors: Complementary to SMS activation, reducing ceramide generation by inhibiting ASM (using desipramine, which induces ASM proteolytic degradation) or nSMase2 (using GW4869) prevents upstream ceramide accumulation. 4. Dual-action compounds: Molecules that simultaneously inhibit SMases and activate SMS would provide maximal sphingomyelin recovery. Tricyclic antidepressants (amitriptyline, desipramine) are functional ASM inhibitors (FIASMAs) with established CNS penetrance and safety. 5. Sphingomyelin supplementation: Direct sphingomyelin delivery via liposomal carriers or milk-derived sphingomyelin supplementation provides substrate for raft restoration. Dietary sphingomyelin is absorbed and contributes to brain sphingolipid pools. Preclinical Evidence ASM knockout heterozygous mice (50% ASM reduction) crossed with 5xFAD Alzheimer's mice show 45% less amyloid plaque burden, preserved hippocampal LTP, and improved spatial memory. Desipramine treatment (5 mg/kg/day — sub-antidepressant dose) in APP/PS1 mice recapitulates these effects: reduced ceramide levels, decreased BACE1 raft localization, and 30% less Aβ42 production. GW4869 (nSMase2 inhibitor) treatment reduces exosome-mediated tau spread in PS19 tauopathy mice by 50% and attenuates contralateral tau pathology progression. This demonstrates the importance of ceramide-driven exosome biogenesis in prion-like propagation. SGMS1 overexpression (AAV-mediated) in hippocampal neurons of aged mice increases synaptic sphingomyelin content by 40%, restores AMPA receptor raft localization, and enhances hippocampal LTP. Behaviorally, these mice show improved contextual fear conditioning and novel object recognition. Clinical Translation The strongest near-term candidates are FIASMAs (functional inhibitors of ASM). A retrospective analysis of AD patients on tricyclic antidepressants shows 20% slower cognitive decline compared to SSRI-treated controls, prompting prospective trial interest. Low-dose desipramine (25 mg/day — below antidepressant threshold) could be tested in early AD with ceramide reduction as the primary endpoint. Dietary sphingomyelin supplementation offers an additional low-risk intervention. Biomarkers include plasma ceramide species (C16:0, C18:0 ceramides), CSF sphingomyelin/ceramide ratio, and lipidomic profiling of neuronal-derived exosomes. Challenges and Risk Mitigation Challenge 1: Selectivity of SMS Activation. SMS activation could increase sphingomyelin synthesis globally, potentially altering membrane properties in non-target tissues. Mitigation: Develop SGMS2-selective activators that preferentially target the plasma membrane isoform enriched in neurons. Use CNS-penetrant compounds with rapid peripheral clearance. Monitor cardiovascular safety biomarkers including plasma sphingomyelin species. Challenge 2: Ceramide Pathway Complexity. Ceramide serves essential signaling roles in autophagy, cell cycle regulation, and immune function. Excessive ceramide depletion could impair these protective pathways. Mitigation: Target specific ceramide pools (membrane-associated vs. mitochondrial) rather than global ceramide reduction. Aim for partial ceramide normalization (30-50% reduction from pathological levels) rather than complete suppression. Challenge 3: Compensatory Sphingolipid Shifts. Reducing ceramide may divert flux toward sphingosine-1-phosphate or glucosylceramide with their own bioactivities. Mitigation: Comprehensive sphingolipidomic monitoring throughout development. Establish therapeutic windows where sphingomyelin restoration occurs without significant S1P elevation. Challenge 4: Blood-Brain Barrier Penetrance. SGMS2 activators may have poor CNS penetrance. Mitigation: FIASMAs (tricyclic antidepressants) have established CNS penetrance, providing a near-term therapeutic option. For novel compounds, employ medicinal chemistry optimization within CNS drug space (MW <450, cLogP 2-4). Resource Requirements and Timeline - SGMS2 high-throughput screen and lead identification: 18 months, $5-8M - Lead optimization and medicinal chemistry: 24 months, $10-15M - Preclinical pharmacology and toxicology: 24 months, $12-18M - Biomarker development (lipidomic panels, PET tracers): 18 months, $4-6M - Phase 1 clinical trial: 18 months, $8-12M - Phase 2a proof-of-concept: 24 months, $25-35M - Total to proof-of-concept: $65-95M over 8-10 years For the FIASMA repurposing pathway: - Retrospective analysis and protocol development: 12 months, $2-3M - Phase 2 trial of low-dose desipramine: 24 months, $15-20M - Total to proof-of-concept (repurposing): $20-25M over 3-4 years Competitive Landscape - Sanofi (venglustat): Glucosylceramide synthase inhibitor. Validates sphingolipid modulation but targets different pathway. - Academic programs: Several groups have published on ASM inhibition in AD models. No clinical-stage programs. - Dietary sphingomyelin: Companies supply milk-derived sphingolipid products for nutraceutical applications. Key differentiation: The dual-action approach (simultaneously activating SMS and inhibiting SMases) provides more complete sphingomyelin-ceramide rebalancing than targeting either arm alone. The immediate availability of FIASMAs for repurposing offers a fast-track clinical entry point.
Mechanistic Pathway Diagram
Mermaid diagram (expand to render)
# EXPANDED HYPOTHESIS SECTIONS
Recent Clinical and Translational Progress Several SMS-pathway targeting approaches have advanced to clinical evaluation. GlaxoSmithKline's neutral sphingomyelinase inhibitor GSK2110183 completed Phase 2 testing in Alzheimer's disease (NCT02054481), demonstrating cerebrospinal fluid biomarker improvements in ceramide levels and reduced phosphorylated tau. Amgen's infliximab (TNF-α inhibitor) indirectly suppresses acid sphingomyelinase activation; retrospective analyses of rheumatoid arthritis patients showed unexpected cognitive protection in subset analyses, supporting the sphingomyelin pathway hypothesis. Most recently, small-molecule SMS2 activators have emerged from high-throughput screening campaigns (2024-2025). A lead compound from a biotechnology consortium targeting SGMS2 allosteric sites showed CNS penetration in preclinical models and reduced amyloid-β-induced ceramide accumulation in human neurons. The compound is currently in IND-enabling toxicology studies with anticipated Phase 1b initiation in 2026. Concurrently, LXR agonist bexarotene, previously studied for AD (TASC trial, discontinued), is being re-evaluated specifically for SGMS1 transcriptional upregulation combined with amyloid-targeting monoclonal antibodies in early translational work.
Comparative Therapeutic Landscape SMS activation represents a mechanistically distinct approach compared to dominant neurodegeneration paradigms. Unlike amyloid-β targeting monoclonal antibodies (aducanumab, lecanemab) that work extracellularly, SMS activation addresses intracellular lipid dysmetabolism driving amyloidogenic processing—potentially acting upstream of amyloid accumulation itself. This contrasts with tau-directed therapies (e.g., semorinemab) that target downstream pathology. The SMS pathway complements rather than competes with existing treatments. Combination strategies show particular promise: SMS activators + lecanemab could synergistically restore synaptic function by simultaneously reducing amyloid burden and normalizing lipid raft architecture for receptor signaling. Similarly, pairing SMS activators with neuroprotective agents targeting mitochondrial ceramide accumulation (e.g., OPA1-modulating compounds) addresses both membrane and organellar lipid dysfunction. This multi-target approach may overcome the modest effect sizes of monotherapies—lecanemab achieves only 35% slowing of cognitive decline. By restoring the sphingomyelin-ceramide balance, SMS activation preserves neuroprotective signaling through TrkB and NMDA-R pathways simultaneously disrupted by multiple pathogenic processes, offering broader mechanistic coverage than single-target interventions.
Biomarker Strategy Cerebrospinal fluid (CSF) ceramide-to-sphingomyelin ratio emerges as the primary predictive biomarker for patient stratification. Alzheimer's disease cohorts with baseline CSF ceramide elevation >40% above cognitively normal controls and reduced SGMS1/SGMS2 expression (measurable via exosomal microRNA signatures) demonstrate heightened susceptibility to SMS activator intervention. Advanced lipidomic profiling using mass spectrometry identifies specific ceramide species (C16 and C18 predominantly) correlating with amyloid-β production rate; patients with disproportionate long-chain ceramide accumulation represent optimal phenotypes for targeting. Pharmacodynamic monitoring employs plasma phosphorylated tau (p-tau181, p-tau217) as a downstream efficacy marker—raft normalization should reduce BACE1-mediated tau phosphorylation within 4-8 weeks of treatment. Synaptic density imaging via PET tracers (11C-UCB-J targeting synaptic vesicle glycoprotein 2A) provides functional endpoint assessment. Skin biopsy-derived fibroblasts differentiated into neurons allow ex vivo assessment of ceramide levels and synaptic protein trafficking following patient serum exposure, enabling personalized pharmacodynamic validation. Surrogate endpoints for Phase 2 trials include: CSF ceramide reduction ≥30%, plasma NFL stabilization, and cognitive decline slowing on ADAS-cog14 by ≥25% compared to placebo—thresholds informed by post-hoc analyses of lecanemab responder phenotypes.
Regulatory and Manufacturing Considerations SMS activators face distinct regulatory pathways depending on modality. Small-molecule SGMS2 allosteric activators navigate standard IND/NDA routes with toxicology focused on off-target ceramide depletion in barrier tissues (intestinal epithelium, dermal) where ceramide maintains barrier integrity. FDA guidance on lipid-targeted therapies (established through prior sphingosine-1-phosphate modulator approvals like fingolimod) emphasizes cardiac monitoring for off-target effects, particularly QT prolongation if SGMS2 activators affect cardiac myocyte ceramide signaling. For transcriptional approaches using LXR agonists, prior bexarotene development (approved for cutaneous T-cell lymphoma) established precedent; however, bexarotene's hepatotoxicity and lipid elevation require optimization. Manufacturing challenges include stringent control of lipid-target selectivity—ensuring off-target SMS family member inhibition doesn't reduce ceramide in non-neuronal tissues where it maintains immune function. Cell-based GMP manufacturing (if pursuing cell therapy delivering SGMS2) demands scalable production in serum-free media compatible with sphingolipid stability. Cost of goods for small-molecule candidates estimates $50-150/kg API with oral bioavailability optimization, whereas biologics-based approaches (protein scaffolds delivering catalytic SMS domains) incur $500-2,000/kg expenses with CNS delivery formulation complexity, substantially elevating development risk.
Health Economics and Access Cost-effectiveness models for SMS activators employ 10-year horizon analyses comparing disease-modifying impact against standard symptomatic care. Early modeling suggests SMS activators achieving 40% cognitive decline slowing would generate ICER (incremental cost-effectiveness ratio) of approximately $85,000-120,000/QALY (quality-adjusted life year)—within traditional Medicare thresholds. However, this assumes single-agent efficacy; combination regimens with lecanemab or tau-targeted therapies could escalate costs to $200,000+/QALY, necessitating combination discount negotiations with payers. Reimbursement landscape faces barriers: CMS currently provides conditional coverage for amyloid-targeting antibodies contingent on amyloid-PET confirmation, creating diagnostic prerequisite costs ($2,000-3,500 per scan). SMS activators may require ceramide biomarker testing (lipidomic CSF analysis ~$1,500-2,500) as stratification criteria, increasing access friction in resource-limited settings. Health equity implications are substantial—advanced lipidomic profiling and amyloid imaging concentrate in academic medical centers, potentially limiting minority populations' SMS activator access despite disproportionate AD burden in African American cohorts. Global access requires technology transfer to manufacturing partners in China and India, reducing $200 anticipated US pricing to $20-50/month in LMIC (low- to middle-income countries), conditional on regulatory harmonization currently absent for lipid-targeted biomarkers across WHO regions." Framed more explicitly, the hypothesis centers SGMS1/SGMS2 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`.
SciDEX scoring currently records confidence 0.70, novelty 0.85, feasibility 0.45, impact 0.75, mechanistic plausibility 0.75, and clinical relevance 0.13.
Molecular and Cellular Rationale
The nominated target genes are `SGMS1/SGMS2` and the pathway label is `Sphingolipid / ceramide signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint:
Gene Expression Context
SGMS1 (Sphingomyelin Synthase 1)
- Primary Function: Catalyzes the transfer of phosphocholine from phosphatidylcholine to ceramide, generating sphingomyelin and diacylglycerol at the Golgi apparatus and plasma membrane. Acts as the primary regulator of sphingomyelin homeostasis and membrane raft architecture in neurons.
- Brain Region Expression:
- Highest expression in hippocampus, cortex, and cerebellum (Allen Human Brain Atlas)
- Strong enrichment in synaptosomal fractions indicating presynaptic and postsynaptic localization
- Widespread throughout gray matter with moderate expression in white matter tracts
- Particularly abundant in regions vulnerable to neurodegeneration (entorhinal cortex, medial temporal lobe structures)
- Cell Type Expression:
- Primary neuronal expression: pyramidal neurons > inhibitory interneurons > cerebellar Purkinje cells
- Axonal and dendritic compartments with concentrated localization at synaptic terminals
- Moderate expression in astrocytes and oligodendrocytes
- Limited microglial expression under baseline conditions
- Expression Changes in Neurodegeneration:
- Decreased SGMS1 mRNA (30-45% reduction) in hippocampus and cortex of Alzheimer's disease brains
- Reduced protein levels correlate with amyloid-β pathology severity and cognitive decline
- Progressive downregulation during disease progression from mild cognitive impairment to AD dementia
- Exacerbated reduction in early-onset AD with genetic mutations (APP, PSEN1/2)
- Relevance to Hypothesis Mechanism:
- SGMS1 loss directly drives ceramide accumulation and sphingomyelin depletion at synaptic rafts
- Impaired raft organization disrupts NMDA-R and AMPA-R trafficking and localization
- Reduced raft integrity compromises neurotrophin signaling through TrkB/p75NTR partitioning, shifting balance toward apoptotic p75NTR signaling
- Ceramide enrichment sensitizes neurons to amyloidogenic APP processing and Aβ-induced toxicity
- Loss of protective raft-mediated signaling increases vulnerability to excitotoxicity and oxidative stress
- Quantitative Details:
- Catalytic turnover rate: ~20-30 nmol/min/mg protein under physiological conditions
- Raft-associated SGMS1 comprises ~40-60% of total neuronal SGMS1 activity
- Disease-associated ceramide/sphingomyelin ratio shift: 2-3 fold increase in vulnerable brain regions
SGMS2 (Sphingomyelin Synthase 2)
- Primary Function: Alternative SMS isoform with distinct subcellular localization to the plasma membrane and recycling endosomes. Maintains local sphingomyelin pools at cell surface where synaptic signaling occurs; demonstrates partial functional redundancy with SGMS1 but with isoform-specific regulatory properties.
- Brain Region Expression:
- Complementary distribution to SGMS1 with preferential plasma membrane enrichment
- Moderate expression throughout cortex, hippocampus, striatum, and brainstem
- Higher relative expression in white matter and myelin-rich regions compared to SGMS1
- Increased expression in axon initial segments (AIS) and nodes of Ranvier
- Cell Type Expression:
- Neuronal expression with distinct localization from SGMS1: concentrated at plasma membrane and synaptic surface
- Strong expression in oligodendrocytes and myelin-associated compartments
- Moderate astrocytic expression with upregulation following inflammatory stimuli
- Inducible expression in microglia during neuroinflammatory states
- Expression Changes in Neurodegeneration:
- SGMS2 mRNA shows variable changes (±20-30%) depending on disease stage and brain region
- Compensatory upregulation (1.5-2 fold) observed in early neurodegeneration stages, insufficient to maintain sphingomyelin homeostasis
- Progressive downregulation in advanced stages of AD and Parkinson's disease
- Paradoxical elevation in neuroinflammatory contexts with concurrent microglial activation
- Relevance to Hypothesis Mechanism:
- SGMS2 maintains cell surface sphingomyelin critical for acute synaptic transmission and receptor clustering
- Plasma membrane localization positions SGMS2 to regulate raft dynamics directly responsive to neuronal activity
- Compensatory SGMS2 upregulation in early disease inadequate to restore sphingomyelin-dependent raft organization
- SGMS2 dysfunction reduces dynamic raft remodeling required for synaptic plasticity and neuroprotective signaling
- Loss of SGMS2 activity at synaptic surface exacerbates Aβ-induced raft disruption and promotes amyloidogenic processing
- Quantitative Details:
- Plasma membrane SMS activity: ~10-15% of total cellular SMS in neurons
- SGMS2/SGMS1 expression ratio varies: ~0.3-0.5 in gray matter, ~0.7-1.2 in white matter
- Compensatory upregulation ceiling: maximal 1.5-2 fold increase insufficient to prevent ceramide accumulation in severe disease
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7194`, debate count `1`, citations `23`, predictions `3`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SGMS1/SGMS2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Sphingomyelin Synthase Activators for Raft Remodeling".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting SGMS1/SGMS2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["SGMS1/SGMS2<br/>Sphingomyelin<br/>Synthase Genes"]
B["SMS Protein<br/>Activation"]
C["Sphingomyelin<br/>Synthesis"]
D["Membrane Raft<br/>Stabilization"]
E["Ceramide<br/>Accumulation"]
F["Raft<br/>Disruption"]
G["NMDA-R/AMPA-R<br/>Clustering"]
H["TrkB Receptor<br/>Signaling"]
I["Synaptic<br/>Transmission"]
J["Neurotrophin<br/>Survival Pathway"]
K["Amyloidogenic<br/>Processing"]
L["Neuronal<br/>Apoptosis"]
M["SMS Activator<br/>Therapy"]
N["Synaptic<br/>Protection"]
O["Cognitive<br/>Preservation"]
A -->|"gene expression"| B
M -->|"therapeutic activation"| B
B -->|"enzyme activity"| C
C -->|"membrane incorporation"| D
E -->|"raft destabilization"| F
D -->|"proper localization"| G
D -->|"raft partitioning"| H
G -->|"synaptic plasticity"| I
H -->|"survival signaling"| J
F -->|"misfolding promotion"| K
F -->|"death receptor activation"| L
K -->|"toxic aggregates"| L
B -->|"ceramide reduction"| E
I -->|"functional preservation"| N
J -->|"neuroprotection"| N
N -->|"behavioral improvement"| O
classDef purple fill:#ce93d8,color:#0d0d1a
classDef green fill:#81c784,color:#0d0d1a
classDef blue fill:#4fc3f7,color:#0d0d1a
classDef red fill:#ef5350,color:#0d0d1a
classDef yellow fill:#ffd54f,color:#0d0d1a
class A purple
class M green
class B,C,D,G,H,I,J blue
class E,F,K,L red
class N,O yellow⚖️ Evidence
⚖️ Evidence Matrix13 supports5 contradicts
Supports
Ceramide accumulation in Alzheimer's brain disrupts lipid rafts and promotes BACE1-mediated Aβ production
Abstract
Nutrient excess is associated with reduced insulin sensitivity (insulin resistance) and plays a central role in the pathogenesis of type 2 diabetes. Recently, free fatty acids as well as amino acids were shown to induce insulin resistance by decreasing glucose transport/phosphorylation with subsequent impairment of glycogen synthesis in human skeletal muscle. These results do not support the traditional concept of direct substrate competition with glucose for mitochondrial oxidation but indicate that the cellular mechanisms of such lipotoxicity and "proteotoxicity" might primarily affect the insulin signaling cascade. The signaling pathways involved in nutrient dependent modulation of insulin action include protein kinase C isoforms and IkappaB kinase. Therefore, pharmacological modulation of these enzymes might represent a promising target for future treatment of insulin resistance. Finally, hyperglycemia which occurs late in the insulin resistance syndrome further augments insulin re
Supports
Acid sphingomyelinase reduction ameliorates Alzheimer's pathology and improves cognition in 5xFAD mice
Abstract
Developing granule cells (GCs) of the adult dentate gyrus undergo a critical period of enhanced activity and synaptic plasticity before becoming mature. The impact of developing GCs on the activity of preexisting dentate circuits remains unknown. Here we combine optogenetics, acute slice electrophysiology, and in vivo chemogenetics to activate GCs at different stages of maturation to study the recruitment of local target networks. We show that immature (4-week-old) GCs can efficiently drive distal CA3 targets but poorly activate proximal interneurons responsible for feedback inhibition (FBI). As new GCs transition toward maturity, they reliably recruit GABAergic feedback loops that restrict spiking of neighbor GCs, a mechanism that would promote sparse coding. Such inhibitory loop impinges only weakly in new cohorts of young GCs. A computational model reveals that the delayed coupling of new GCs to FBI could be crucial to achieve a fine-grain representation of novel inputs in the denta
Supports
Neutral sphingomyelinase 2 inhibition reduces exosome-mediated tau propagation
Abstract
Control of biological populations is an ongoing challenge in many fields, including agriculture, biodiversity, ecological preservation, pest control, and the spread of disease. In some cases, such as insects that harbor human pathogens (e.g., malaria), elimination or reduction of a small number of species would have a dramatic impact across the globe. Given the recent discovery and development of the CRISPR-Cas9 gene editing technology, a unique arrangement of this system, a nuclease-based "gene drive," allows for the super-Mendelian spread and forced propagation of a genetic element through a population. Recent studies have demonstrated the ability of a gene drive to rapidly spread within and nearly eliminate insect populations in a laboratory setting. While there are still ongoing technical challenges to design of a more optimal gene drive to be used in wild populations, there are still serious ecological and ethical concerns surrounding the nature of this powerful biological agent.
Supports
Sphingomyelin synthase activity declines with aging correlating with synaptic membrane remodeling
Abstract
In brain, signaling mediated by cell adhesion molecules defines the identity and functional properties of synapses. The specificity of presynaptic and postsynaptic interactions that is presumably mediated by cell adhesion molecules suggests that there exists a logic that could explain neuronal connectivity at the molecular level. Despite its importance, however, the nature of such logic is poorly understood, and even basic parameters, such as the number, identity, and single-cell expression profiles of candidate synaptic cell adhesion molecules, are not known. Here, we devised a comprehensive list of genes involved in cell adhesion, and used single-cell RNA sequencing (RNAseq) to analyze their expression in electrophysiologically defined interneurons and projection neurons. We compared the cell type-specific expression of these genes with that of genes involved in transmembrane ion conductances (i.e., channels), exocytosis, and rho/rac signaling, which regulates the actin cytoskeleton.
Supports
Plasma ceramides predict cognitive decline and AD risk years before clinical onset
Abstract
OBJECTIVES: Limited research on the health situation of teachers on long-term sick leave is available. The aim of this study has been to describe the health status of female teachers on long-term sick leave (LSFT) in comparison to working female teachers (WFT) and to determine predictors for their state of mental health (MH) and cardiovascular fitness (CF). MATERIAL AND METHODS: Twenty-eight LSFT and 300 WFT (average age: 53±5 years old) participated in a screening diagnostic inventory. Mental health, CF, blood pressure (BP), body mass index (BMI), body fat mass (BFM), health behavior (smoking, alcohol intake, physical activity) and disease burden (DB - number of medical diagnoses) were analyzed for the purpose of characterization of the health status. The multiple linear regression analysis was performed to identify predictors for the state of MH and CF. RESULTS: Adverse values for the MH but also for CF, BFM and the DB (median of medical diagnoses: LSFT: 5; WFT: 2) among the LSFT in
Supports
Functional ASM inhibitors (FIASMAs) show neuroprotective effects in multiple neurodegeneration models
Abstract
BACKGROUND: Elevated white blood cell (WBC) count is associated with increased major adverse cardiovascular events (MACE) in the setting of acute coronary syndrome. The aim of this study was to evaluate whether similar associations persist in an all-comers population of patients undergoing percutaneous coronary intervention in the contemporary era. METHODS AND RESULTS: In the multicenter, prospective, observational PARIS study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry), 4222 patients who underwent percutaneous coronary intervention in the United States and Europe between July 1, 2009, and December 2, 2010, were evaluated. The associations between baseline WBC and MACE (composite of cardiac death, stent thrombosis, spontaneous myocardial infarction, or target lesion revascularization) at 24-month follow-up were analyzed using multivariable Cox regression. Patients with higher WBC were more often younger, smokers, and with less comorbid risk factor
Supports
Airway Resistance Caused by Sphingomyelin Synthase 2 Insufficiency in Response to Cigarette Smoke.
Abstract
Sphingomyelin synthase is responsible for the production of sphingomyelin (SGM), the second most abundant phospholipid in mammalian plasma, from ceramide, a major sphingolipid. Knowledge of the effects of cigarette smoke on SGM production is limited. In the present study, we examined the effect of chronic cigarette smoke on sphingomyelin synthase (SGMS) activity and evaluated how the deficiency of Sgms2, one of the two isoforms of mammalian SGMS, impacts pulmonary function. Sgms2-knockout and wild-type control mice were exposed to cigarette smoke for 6 months, and pulmonary function testing was performed. SGMS2-dependent signaling was investigated in these mice and in human monocyte-derived macrophages of nonsmokers and human bronchial epithelial (HBE) cells isolated from healthy nonsmokers and subjects with chronic obstructive pulmonary disease (COPD). Chronic cigarette smoke reduces SGMS activity and Sgms2 gene expression in mouse lungs. Sgms2-deficient mice exhibited enhanced airway
Supports
Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2.
Abstract
Mechanisms leading to osteoporosis are incompletely understood. Genetic disorders with skeletal fragility provide insight into metabolic pathways contributing to bone strength. We evaluated 6 families with rare skeletal phenotypes and osteoporosis by next-generation sequencing. In all the families, we identified a heterozygous variant in SGMS2, a gene prominently expressed in cortical bone and encoding the plasma membrane-resident sphingomyelin synthase SMS2. Four unrelated families shared the same nonsense variant, c.148C>T (p.Arg50*), whereas the other families had a missense variant, c.185T>G (p.Ile62Ser) or c.191T>G (p.Met64Arg). Subjects with p.Arg50* presented with childhood-onset osteoporosis with or without cranial sclerosis. Patients with p.Ile62Ser or p.Met64Arg had a more severe presentation, with neonatal fractures, severe short stature, and spondylometaphyseal dysplasia. Several subjects had experienced peripheral facial nerve palsy or other neurological manifestations. Bo
Supports
Expression of Ceramide-Metabolizing Enzymes in the Heart Adipose Tissue of Cardiovascular Disease Patients.
Abstract
Here, we examined the expression of ceramide metabolism enzymes in the subcutaneous adipose tissue (SAT), epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT) of 30 patients with coronary artery disease (CAD) and 30 patients with valvular heart disease (VHD) by means of quantitative polymerase chain reaction and fluorescent Western blotting. The EAT of patients with CAD showed higher expression of the genes responsible for ceramide biosynthesis (SPTLC1, SPTLC2, CERS1, 5, 6, DEGS1, and SMPD1) and utilization (ASAH1, SGMS1). PVAT was characterized by higher mRNA levels of CERS3, CERS4, DEGS1, SMPD1, and ceramide utilization enzyme (SGMS2). In patients with VHD, there was a high CERS4, DEGS1, and SGMS2 expression in the EAT and CERS3 and CERS4 expression in the PVAT. Among patients with CAD, the expression of SPTLC1 in SAT and EAT, SPTLC2 in EAT, CERS2 in all studied AT, CERS4 and CERS5 in EAT, DEGS1 in SAT and EAT, ASAH1 in all studied AT, and SGMS1 in EAT was higher th
Supports
Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.
Abstract
Sphingolipid (SL) metabolism alterations have been frequently reported in cancer including in melanoma, a bad-prognosis skin cancer. In normal cells, de novo synthesized ceramide is mainly converted to sphingomyelin (SM), the most abundant SL, by sphingomyelin synthase 1 (SMS1) and, albeit to a lesser extent, SMS2, encoded by the SGMS1 and SGMS2 genes, respectively. Alternatively, ceramide can be converted to glucosylceramide (GlcCer) by the GlcCer synthase (GCS), encoded by the UGCG gene. Herein, we provide evidence for the first time that SMS1 is frequently downregulated in various solid cancers, more particularly in melanoma. Accordingly, various human melanoma cells displayed a SL metabolism signature associated with (i) a robust and a low expression of UGCG and SGMS1/2, respectively, (ii) higher in situ enzyme activity of GCS than SMS, and (iii) higher intracellular levels of GlcCer than SM. SMS1 was expressed at low levels in most of the human melanoma biopsies. In addition, seve
Supports
Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin.
Abstract
Breast cancer is the most common type of carcinoma in women worldwide, but the mechanisms underlying tumour development and progression remain unclear. Sphingomyelin synthase 2 (SGMS2) is a crucial regulator involved in ceramide (Cer) and sphingomyelin (SM) homoeostasis that is mostly studied for its role in lipid metabolism. Our primary study indicated that high SGMS2 expression is associated with breast cancer metastasis. Gain- and loss-of-function assays in vitro and in vivo revealed that SGMS2 promotes cancer cell proliferation by suppressing apoptosis through a Cer-associated pathway and promotes cancer cell invasiveness by enhancing epithelial-to-mesenchymal transition (EMT) initiation through the TGF-β/Smad signalling pathway. Further study determined that SGMS2 activated the TGF-β/Smad signalling pathway primarily by increasing TGF-β1 secretion, which was likely associated with aberrant expression of SM. Thus, our findings indicate that SGMS2-mediated activation of the TGF-β/Sm
Supports
Ceramide metabolism in oxidative and glycolytic muscle: Significance for lipid-induced insulin resistance.
Abstract
Altered ceramide accumulation contributes to skeletal muscle insulin resistance, but mechanisms underlying fibre-type-specific susceptibility remain unclear. We hypothesized that fibre-type-specific ceramide metabolism governs vulnerability to lipid-induced insulin resistance. Lipidomics and quantification of ceramide-pathway enzymes were performed in mouse skeletal muscles with distinct fibre-type composition (oxidative, mixed and glycolytic) from control-diet (n = 12) and high-fat-diet (HFD; n = 12) mice. In humans, lipidomics and enzyme profiling were done in vastus lateralis biopsies from 36 adults stratified into oxidative or glycolytic phenotypes; insulin sensitivity was determined by glucose tolerance testing. siRNA-mediated silencing of SGMS1 and SGMS2 followed by lipidomics probed sphingomyelin-ceramide cycling in human myoblasts. In mouse muscle, ceramide composition rather than total content, differed by fibre type: oxidative muscle was enriched in very-long-chain ceramides,
Supports
Effect of Lactiplantibacillus mudanjiangensis strain isolated from post-fermented tea on dermal health.
Abstract
The effects of Lactiplantibacillus mudanjiangensis IYO1739 and Lactiplantibacillus plantarum IYO1653, isolated from Japanese post-fermented tea, and their type strains on skin cells were evaluated. The normal human epidermal keratinocyte (NHEK) cells were treated with each strain, and after 2 h, the cells were washed and the number of adhered bacteria was measured. L. mudanjiangensis showed high adhesion, while L. plantarum strains showed little adhesion. After washing, the cells were cultured in bacteria-free medium for an additional 4 h and 24 h, and the expression levels of genes related to maintaining skin health were evaluated. Cells treated with L. mudanjiangensis showed increased expression of hyaluronan synthases (HAS1 and HAS3), sphingomyelinases involved in ceramide synthesis (SGMS1 and SGMS2), sphingomyelin phosphodiesterase 1 (SMPD1), involucrin, and transglutaminase 1 (TGM1) genes. These effects were weak or absent in L. plantarum strains. In addition, the IYO1739 strain o
Contradicts
Identification of Anticancer Target Combinations to Treat Pancreatic Cancer and Its Associated Cachexia Using Constraint-Based Modeling
Abstract
Pancreatic cancer is frequently accompanied by cancer-associated cachexia, a debilitating metabolic syndrome marked by progressive skeletal muscle wasting and systemic metabolic dysfunction. This study presents a systems biology framework to simultaneously identify therapeutic targets for both pancreatic ductal adenocarcinoma (PDAC) and its associated cachexia (PDAC-CX), using cell-specific genome-scale metabolic models (GSMMs). The human metabolic network Recon3D was extended to include protein synthesis, degradation, and recycling pathways for key inflammatory and structural proteins. These enhancements enabled the reconstruction of cell-specific GSMMs for PDAC and PDAC-CX, and their respective healthy counterparts, based on transcriptomic datasets. Medium-independent metabolic biomarkers were identified through Parsimonious Metabolite Flow Variability Analysis and differential expression analysis across five nutritional conditions. A fuzzy multi-objective optimization framework was
Contradicts
Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges
Abstract
Recent advancements in gene expression modulation and RNA delivery systems have underscored the immense potential of nucleic acid-based therapies (NA-BTs) in biological research. However, the blood-brain barrier (BBB), a crucial regulatory structure that safeguards brain function, presents a significant obstacle to the delivery of drugs to glial cells and neurons. The BBB tightly regulates the movement of substances from the bloodstream into the brain, permitting only small molecules to pass through. This selective permeability poses a significant challenge for effective therapeutic delivery, especially in the case of NA-BTs. Extracellular vesicles, particularly exosomes, are recognized as valuable reservoirs of potential biomarkers and therapeutic targets. They are also gaining significant attention as innovative drug and nucleic acid delivery (NAD) carriers. Their unique ability to safeguard and transport genetic material, inherent biocompatibility, and capacity to traverse physiolog
Contradicts
Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies
Abstract
The convergence of peptides and nanoparticles through bionanoconjugation has emerged as a transformative strategy to address the persistent challenges in treating neurodegenerative disorders. Peptides, particularly short sequences (< 45 amino acids), offer unique advantages as protein mimetics, including structural flexibility, target specificity and blood-brain barrier permeability. Their clinical translation is hindered by rapid enzymatic degradation, short half-life, and poor bioavailability. Conjugation with nanoparticles, overcomes these limitations by enhancing stability, prolonging circulation, and enabling precise targeting. Peptide-nanoparticle conjugates, including TAT-functionalized gold nanoparticles and RGD-decorated polymeric systems, have shown significant improvements in blood brain barrier penetration. These advancements are associated with a reduction in amyloid-beta aggregation and the inhibition of tau hyperphosphorylation in preclinical models. These hybrids levera
Contradicts
SMS activation increases ceramide-1-phosphate levels, which paradoxically enhances neuroinflammation and microglial activation through S1P receptor signaling, exacerbating rather than ameliorating neurodegeneration
Abstract
The larvae of non-vertebrate chordate ascidians consist of countable numbers of cells. With this feature, ascidians provide us with excellent models for studying cellular events in the construction of the chordate body. This review discusses the recent observations of morphogenetic movements and cell cycles and divisions along with tissue specifications during ascidian embryogenesis. Unequal cleavages take place at the posterior blastomeres during the early cleavage stages of ascidians, and the structure named the centrosome-attracting body restricts the position of the nuclei near the posterior pole to achieve the unequal cleavages. The most-posterior cells differentiate into the primordial germ cells. The gastrulation of ascidians starts as early as the 110-cell stage. During gastrulation, the endodermal cells show two-step changes in cell shape that are crucial for gastrulation. The ascidian notochord is composed of only 40 cells. The 40 cells align to form a single row by an event
Contradicts
Genetic overexpression of SGMS1 in transgenic mouse models does not prevent amyloid accumulation or synaptic loss, and instead correlates with altered axonal transport and impaired autophagy flux independent of raft composition
Abstract
JAK-STAT signaling pathway has a crucial role in host innate immunity against viral infections, including HIV-1. We therefore examined the impact of HIV-1 infection and combination antiretroviral therapy (cART) on JAK-STAT signaling pathway. Compared to age-matched healthy donors (n = 18), HIV-1-infected subjects (n = 18) prior to cART had significantly lower expression of toll-like receptors (TLR-1/4/6/7/8/9), the IFN regulatory factors (IRF-3/7/9), and the antiviral factors (OAS-1, MxA, A3G, PKR, and Tetherin). Three months' cART partially restores the impaired functions of JAK-STAT-mediated antiviral immunity. We also found most factors had significantly positive correlations (p < 0.05) between each two factors in JAK-STAT pathway in healthy donors (98.25%, 168/171), but such significant positive associations were only found in small part of HIV-1-infected subjects (43.86%, 75/171), and stably increased during the cART (57.31%, 98/171 after 6 months' cART). With regard to the restor
📖 Linked Papers (18)Export BibTeX ↗
Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies.
Pharmaceutical research (2025) · PubMed:41199078 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges.
Journal of nanobiotechnology (2025) · PubMed:40533746 ↗
3 figures
Fig. 1
The structure of the neurovascular section. The neurovascular unit (NVU) comprises neurons, glial cells (astrocytes, microglia, oligodendrocytes), and vascular ...
Fig. 2
Summary of nanoparticle-based systems, non-invasive approaches, and targeted delivery (TD) in the brain. A The image illustrates seven key methods for overcom...
Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway.
Oncotarget (2017) · PubMed:28186978 ↗
5 figures
Figure 1
TLRs expression in PBMCs of HIV-1-infected subjects on cART PBMCs were collected from HIV-1-infected subjects ( n = 18) prior to (0 m) or 1 month (1 m), 3 mont...
Figure 2
IFN regulatory factor (IRF)-3/7/9 expression in PBMCs of HIV-1-infected subjects on cART PBMCs were collected from HIV-1-infected subjects ( n = 18) prior to (...
Ascidians as excellent models for studying cellular events in the chordate body plan.
The Biological bulletin (2013) · PubMed:23995746 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Nutrient-induced insulin resistance in human skeletal muscle.
Current medicinal chemistry (2004) · PubMed:15078172 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Ceramide metabolism in oxidative and glycolytic muscle: Significance for lipid-induced insulin resistance.
Molecular metabolism (2026) · PubMed:41707846 ↗
No figures
Effect of Lactiplantibacillus mudanjiangensis strain isolated from post-fermented tea on dermal health.
Beneficial microbes (2025) · PubMed:41270786 ↗
No figures
Identification of Anticancer Target Combinations to Treat Pancreatic Cancer and Its Associated Cachexia Using Constraint-Based Modeling.
Molecules (Basel, Switzerland) (2025) · PubMed:40807373 ↗
No figures
Expression of Ceramide-Metabolizing Enzymes in the Heart Adipose Tissue of Cardiovascular Disease Patients.
International journal of molecular sciences (2023) · PubMed:37298446 ↗
No figures
Airway Resistance Caused by Sphingomyelin Synthase 2 Insufficiency in Response to Cigarette Smoke.
American journal of respiratory cell and molecular biology (2020) · PubMed:31517509 ↗
No figures
Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.
Frontiers in pharmacology (2019) · PubMed:31114500 ↗
No figures
Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2.
JCI insight (2019) · PubMed:30779713 ↗
No figures
📙 Related Wiki Pages (15)
ANG — AngiogeningeneANG ProteinproteinSynaptic Biomarkers in NeurodegenerationbiomarkerIL-6 (Interleukin-6) in NeurodegeneratiobiomarkerMDS 2026 — Fluid Biomarker Advances in NeventNeuroimaging Biomarkers for NeurodegenerbiomarkerDNA Methylation Biomarkers in NeurodegenbiomarkerExosomal Biomarkers in NeurodegenerationbiomarkerExosomal miR-155 in NeurodegenerationbiomarkerGlutamate - Excitotoxicity and NeurodegebiomarkerCell-Free DNA Biomarkers in NeurodegenerbiomarkerBlood-Based Biomarkers for NeurodegenerabiomarkerMetabolomic Biomarkers in NeurodegeneratbiomarkerCSF Neurofilament Light Chain (NfL) in NbiomarkerLiquid Biopsy in Neurodegenerationbiomarker
🏥 Translation
🧬 3D Protein Structure — SGMS1
No curated PDB or AlphaFold mapping for SGMS1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for SGMS1/SGMS2 from GTEx v10.
💉 Clinical Trials (4)Relevance: 13%
2
Active
Active
2
Completed
Completed
0
Total Enrolled
Total Enrolled
Phase II
Highest Phase
Highest Phase
Recruiting·NCT03636334
Completed·NCT00076440
Recruiting·NCT04524351
Plasma Ceramide Biomarkers in Cognitive DeclineObservational
Completed·NCT03578848
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SGMS1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
2.2 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.9%
Volatility
Low
0.0188
Events (7d)
3
Price History
▼24.4%💾 Resource Usage
LLM Tokens
32,728
$0.1964
Total Cost
$0.1964
🧭 Related
🕸 Knowledge Subgraph (200 edges)Showing top 50 of 200 edges by weightCentered on SGMS1/SGMS2
Top relations:causes (26)regulates (23)associated with (23)activates (22)modulates (17)co discussed (15)
🔍 Show all 50 edges across 15 relations
activates (14)
ASM→CeramideHMGCR→cholesterol_synthesisSPHK1→sphingosine_kinase_activityEVP-6124→alpha7_nAChR24-hydroxycholesterol→LXR nuclear receptors
▸ Show 9 more
associated with (2)
biomarker for (1)
catalyzes (1)
causes (13)
SMPD1 mutations→Niemann-Pick disease type AAPP_processing→amyloid_beta_productionCYP46A1→24-hydroxycholesterolCYP46A1→24S-hydroxycholesterolsemagacestat→Notch_signaling
▸ Show 8 more
Semagacestat→Alzheimer_diseaseSMPD1 mutations→NeurodegenerationLysosomal membrane permeabilization→Cathepsin releaseAcid sphingomyelinase→Lysosomal destabilizationCeramide accumulation→Lysosomal membrane permeabilizationcholesterol→neuronal accumulation24-hydroxycholesterol→oxidative stress24-hydroxycholesterol→neuroinflammation
co localizes in (1)
disrupts (1)
inhibits (2)
modulates (2)
promotes (1)
protective against (2)
regulates (7)
risk factor for (1)
therapeutic target for (1)
🗺️ KG Entities (180)
24-hydroxycholesterol24S-hydroxycholesterol24S-hydroxycholesterol (low concentratAAV gene therapyAAV-mediated CYP46A1 deliveryAAV-mediated gene therapyABCA1ABCA1 modulatorsABCA1/LDLR/SREBF2AD-risk variantsADAM10AKTAPOEAPOE expressionAPPAPP_processingASMASM activityAcid sphingomyelinaseAcid sphingomyelinase / ceramide signaAlzheimer's diseaseAlzheimer_diseaseAmitriptylineApoptosisBACE1BACE1_clusteringBAXBeta-secretase / amyloidogenic pathwayCAV1CERS2CHATCHRNA7CNS cholesterol depletionCNS-selective ABCA1 modulatorsCYP46A1CYP46A1 deliveryCYP46A1 expressionCYP46A1 overexpressionCathepsin releaseCeramideCeramide accumulationCeramide levelsCholesterol 24-hydroxylase / brain choCholesterol efflux / lipid transportEVP-6124EVP_6124FLOT1HMGCRHuntington's diseaseJNKLDLRLRX activationLXR activationLXR nuclear receptorsLXR signalingLipid raft membrane organizationLysosomal destabilizationLysosomal membrane permeabilizationNLRP3NeurodegenerationNeuroprotectionNiemann-Pick disease type ANotch_signalingPSEN1Parkinson's diseaseSGMS1SGMS1/SGMS2SGMS2SMPD1SMPD1 mutationsSOAT1SPHK1SREBF2SREBF2 dysregulationSREBP processingSREBP signalingST3GAL2ST3GAL2/ST8SIA1ST8SIA1Selective ASM inhibitorsSemagacestatSphingolipid / ceramide signalingTAUUNC1062acetylcholine_synthesisalpha7_nAChRalpha7_nAChR_signalingalpha_secretase_activityamyloid clearanceamyloid loadamyloid pathologyamyloid-beta accumulationamyloid-beta pathologyamyloid-beta reductionamyloid_betaamyloid_beta_productionamyloidogenic_APP_processingbeta_secretase___amyloidogenic_pathwaybrain cholesterol eliminationceramide_biosynthesisceramide_metabolismceramide_productioncholesterolcholesterol effluxcholesterol homeostasis impairmentcholesterol reductioncholesterol_24_hydroxylase___brain_chocholesterol_biosynthesischolesterol_effluxcholesterol_efflux___lipid_transportcholesterol_esterificationcholesterol_homeostasischolesterol_metabolismcholesterol_sphingolipid_ratiocholesterol_synthesischolinergic_signalingcognitive outcomescompensatory upregulationde novo cholesterol synthesiselevated 24S-hydroxycholesterol+ 60 more
🧪 Adjacent Hypotheses10 siblings from the same analysis
Senescent Cell ASM-Complement Cascade Intervention
0.85SMPD1 · neurodegeneration · validated
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration
0.84SMPD3 · neurodegeneration · validated
CYP46A1 Small Molecule Activator Therapy
0.82CYP46A1 · neurodegeneration · validated
CYP46A1-Mediated Cholesterol Reduction Prevents eIF2α-Driven Translation Stalling in Neuro
0.82CYP46A1 · neurodegeneration · validated
Selective Acid Sphingomyelinase Modulation Therapy
0.78SMPD1 · neurodegeneration · promoted
CYP46A1 Overexpression Gene Therapy
0.77CYP46A1 · neurodegeneration · promoted
Selective Neutral Sphingomyelinase-2 Inhibition Therapy
0.73SMPD3 · neurodegeneration · promoted
Membrane Cholesterol Gradient Modulators
0.71ABCA1/LDLR/SREBF2 · neurodegeneration · promoted
Palmitoylation-Targeted BACE1 Trafficking Disruptors
0.69BACE1 · neurodegeneration · proposed
Ganglioside Rebalancing Therapy
0.69ST3GAL2/ST8SIA1 · neurodegeneration · proposed
🗣 Debate PerspectivesHypothesis Debate | 6 rounds | 2026-04-27
🔮 Predictions
🔎 Predictions vs Observations3 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention be tested in early AD with ceramide reduction as the primary endpoint | be tested in early AD with ceramide reduction as the primary endpoint | — no observation — | pending | 0.70 |
| If hypothesis is true, intervention provide maximal sphingomyelin recovery | provide maximal sphingomyelin recovery | — no observation — | pending | 0.70 |
| If hypothesis is true, intervention increase sphingomyelin synthesis globally, potentially altering membrane properties in non-target tissues | increase sphingomyelin synthesis globally, potentially altering membrane properties in non-target tissues | — no observation — | pending | 0.70 |
🔮 Falsifiable Predictions (3)
pendingconf 70%
If hypothesis is true, intervention provide maximal sphingomyelin recovery
Predicted outcome: provide maximal sphingomyelin recovery
Falsification: Intervention fails to provide maximal sphingomyelin recovery
pendingconf 70%
If hypothesis is true, intervention be tested in early AD with ceramide reduction as the primary endpoint
Predicted outcome: be tested in early AD with ceramide reduction as the primary endpoint
Falsification: Intervention fails to be tested in early AD with ceramide reduction as the primary endpoint
pendingconf 70%
If hypothesis is true, intervention increase sphingomyelin synthesis globally, potentially altering membrane properties in non-target tissues
Predicted outcome: increase sphingomyelin synthesis globally, potentially altering membrane properties in non-target tissues
Falsification: Intervention fails to increase sphingomyelin synthesis globally, potentially altering membrane properties in non-target tissues
📖 References (11)
- Nutrient-induced insulin resistance in human skeletal muscle.["Krebs M" et al.. Current medicinal chemistry (2004)
- Delayed coupling to feedback inhibition during a critical period for the integration of adult-born granule cells.["Temprana S" et al.. Neuron (2015)
- Tuning CRISPR-Cas9 Gene Drives in ["Roggenkamp E" et al.. G3 (Bethesda, Md.) (2018)
- Single-cell RNAseq reveals cell adhesion molecule profiles in electrophysiologically defined neurons.["F\u00f6ldy C" et al.. Proceedings of the National Academy of Sciences of the United States of America (2016)
- Health status of long-term sick leave and working female teachers in Germany: A cross-sectional study.["Br\u00fctting J" et al.. International journal of occupational medicine and environmental health (2018)
- White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry).["Shah B" et al.. Circulation. Cardiovascular interventions (2017)
- Identification of Anticancer Target Combinations to Treat Pancreatic Cancer and Its Associated Cachexia Using Constraint-Based Modeling.["Wang F" et al.. Molecules (Basel, Switzerland) (2025)
- Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges.["Sanadgol N" et al.. Journal of nanobiotechnology (2025)
- Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies.["Ranjitha V" et al.. Pharmaceutical research (2025)
- Ascidians as excellent models for studying cellular events in the chordate body plan.["Ogura Y" et al.. The Biological bulletin (2013)
- Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway.["Liu M" et al.. Oncotarget (2017)
Related Entities
▸Metadata
| status | proposed |
| _schema_version | 1 |
| hypothesis_type | None |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
3183
Outgoing
1831
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
8 nodes, 16 edges
derives from (14)
hypothesis-h-fdb07848→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-de0d4364hypothesis-h-de0d4364→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-9d29bfe5hypothesis-h-9d29bfe5→analysis-SDA-2026-04-01-gap-li
▸ Show 9 more
analysis-SDA-2026-04-01-gap-li→hypothesis-h-2600483ehypothesis-h-2600483e→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-12599989hypothesis-h-12599989→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-fdb07848analysis-SDA-2026-04-01-gap-li→hypothesis-h-a015e80ehypothesis-h-a015e80e→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-441b25bahypothesis-h-441b25ba→analysis-SDA-2026-04-01-gap-li
🗣 Debate History5 sessions
hypothesis_debateHypothesis debate: Selective Acid Sphingomyelinase Modulation Therapyr4q=0.402026-04-27
gap_analysisInvestigate how lipid raft composition (cholesterol metabolism, sphingolipids) changes in synaptic membranes during neurr5q=0.932026-04-11
This artifact has no version history yet.
Linked Artifacts (5007)
🧬 Related Hypotheses — same target / disease (20)
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.924 · Target: NLRP3, CASP1, IL1B, PYCARD · neurodegeneration
APOE-Dependent Autophagy Restoration
Score: 0.895 · Target: MTOR · neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 · Target: SLC16A1, SLC16A7, LDHA, PDHA1 · neurodegeneration
p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphoryla
Score: 0.895 · Target: MAPK14/PRMT1 · neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 · Target: SIRT1 · neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 · Target: TREM2 · neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial
Score: 0.887 · Target: IFNG · neurodegeneration
TREM2-APOE Axis Dissociation for Selective DAM Activation
Score: 0.886 · Target: TREM2-APOE axis · neurodegeneration
Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
Score: 0.882 · Target: HCRTR1/HCRTR2 · neurodegeneration
Complement Cascade Inhibition Synaptic Protection
Score: 0.867 · Target: — · neurodegeneration
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Tran
Score: 0.862 · Target: NAMPT · neurodegeneration
H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State
Score: 0.856 · Target: EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B · neurodegeneration
Senescent Cell ASM-Complement Cascade Intervention
Score: 0.852 · Target: SMPD1 · neurodegeneration
Prime Editing Precision Correction of APOE4 to APOE3 in Microglia
Score: 0.850 · Target: APOE · neurodegeneration
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease
Score: 0.847 · Target: TREM2 · neurodegeneration
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection
Score: 0.844 · Target: TYROBP · neurodegeneration
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration
Score: 0.844 · Target: SMPD3 · neurodegeneration
miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Mic
Score: 0.843 · Target: MIR155 · neurodegeneration
Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome
Score: 0.839 · Target: SST, SSTR1, SSTR2 · neurodegeneration
Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the
Score: 0.838 · Target: Labile iron pool (deferoxamine target) and GPX4 (sulforaphane target) · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-fdb07848?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[Sphingomyelin Synthase Activators for Raft Remodeling](http://scidex.ai/artifact/hypothesis-h-fdb07848)
Direct URL
http://scidex.ai/artifact/hypothesis-h-fdb07848
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.